Terug naar bedrijfspagina

Nieuws over Tubize (Financière De)

28/06/2024 UCB - spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN) (28.06.2024)

26/06/2024 UCB - epilepsy drug BRIVIACT(brivaracetam)1 approved in Japan for treatment of focal onset seizures (26.06.2024)

13/06/2024 UCB -New data support the value of CIMZIA for women living with chronic rheumatic diseases throughout pregnancy and postpartum, and for people living with RA and high rheumatoid factor levels (13.06.2024)

12/06/2024 UCB - to share first presentations of BIMZELX(bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 (12.06.2024)

10/06/2024 UCB - Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps (10.06.2024)

31/05/2024 UCB - announces positive CHMP opinion for two 320 mg device presentations of BIMZELX (bimekizumab) (31.05.2024)

23/05/2024 UCB - announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa (23.05.2024)

18/05/2024 UCB - Media Room: Transparency notification Wellington (18.05.2024)

08/05/2024 UCB - Media Room: UCB presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting (08.05.2024)

25/04/2024 UCB - off to a Good Start into 2024 – Progressing on its Growth Path for a Decade Plus (25.04.2024)

25/04/2024 UCB - off to a Good Start into 2024 – Progressing on its Growth Path for a Decade Plus (25.04.2024)

25/04/2024 UCB - Media Room UCB’s General Meeting of Shareholders 2024 (25.04.2024

24/04/2024 UCB - Transparantieverklaring FMR LLC (24.04.2024)

22/04/2024 UCB - receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa (22.04.2024)

17/04/2024 UCB - FINTEPLA (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) (17.04.2014)

12/04/2024 UCB - Media Room: UCB presents new data highlighting developments across expansive neurology portfolio at 76th AAN Annual Meeting (12.04.2024)

12/04/2024 UCB - Media Room: Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY(romosozumab) can help to close the treatment gap in osteoporosi (12.04.2024)

23/05/2018 Financière de Tubize: upgrade van 'houden' naar 'kopen' (BNP Paribas Fortis)